Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound   Target Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound

---

Query: EC:3.1.3.1 (alkaline phosphatase)
47,916 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Osteoinductive implantable materials have been a subject of basic science research in clinical implantology. This study examined the osteoinductive effect of an implantable material produced by osteoblastic cells that were isolated in the laboratory from mouse calvaria. After 21 days in culture, osteoblastic cells formed a thin film that could be easily manipulated. This thin film was subjected to freezing and thawing and was implanted in mouse muscle tissue. Osteoblastic cells were strongly positive for alkaline phosphatase reactivity and Von Kossa stain in vitro. Collagen type I, osteocalcin (BGP), and alkaline phosphatase were identified at the immunohistochemical electron microscopic level. Histologic findings showed an osteoinductive effect of the implanted material. The results strongly suggest the possibility of producing an osteoinductive implantable material by culturing osteoblastic cells in vitro.
...
PMID:An in vivo evaluation of an osteoinductive implantable material produced by osteoblastic cells in vitro. 815 May 11

Dichloromethylene bisphosphonate (clodronate), an inhibitor of bone resorption, has been administered subcutaneously (1.25 mg/day, 3 consecutive days) to control male albino Wistar rats (n = 8). Variations in the levels of serum alkaline phosphatase (AP) and osteocalcin (BGP), biochemical markers of bone formation, and in urinary hydroxyproline (OH-Prol) and serum tartrate-resistant acid phosphatase (TRAP), markers of bone resorption, have been analyzed. A significant decrease was observed in OH-Prol/creatinine and TRAP. We found a positive correlation between the percentage of decrease, with respect to basal values, of TRAP and OH-Prol/creatinine (p < 0.05). These results suggest that TRAP could be a useful marker to evaluate the changes of bone resorption induced by bisphosphonates in the rat together with the classical marker OH-Prol. A significant decrease was observed in AP. BGP also decreased significantly, but the decrease was relatively small compared to the coefficient of variation of the method. We suggest the preferential use of AP determination, instead of BGP, in the study of the effects produced by bisphosphonates on bone formation in rats, if hepatic function is maintained.
...
PMID:Usefulness of biochemical markers of bone turnover in rats after clodronate administration. 816 18

Serum bone Gla protein (S-BGP), a marker of bone metabolism, was measured in 60 patients included in a staging programme for recurrent breast cancer. Other diagnostic procedures comprised S-alkaline phosphatase (S-AP), bone scan (B-scan), bilateral iliac crest bone marrow biopsies, and radiological bone survey. The sites of recurrence were bone (61%), bone marrow (46%), soft tissue (52%), lung (13%), pleura (11%), liver (4%), and brain (2%). Radiology and bone biopsy served as key diagnoses as to the presence or absence of bone metastases. The diagnostic efficiency of B-scan and S-AP was greater than that of S-BGP, and the result of BGP measurement was associated with neither extent nor number of bone metastases. However, the BGP values were significantly lower in patients who had visceral metastases, and the median duration of survival after recurrence was 13 months for patients with low S-BGP levels (= < 2.0 nmol l-1), compared to 18 months for patients with medium S-BGP values (2.0-2.9 nmol l-1), and 25 months for patients with high values (> 3.0 nmol l-1) (p = 0.19). Analyses of the simultaneous effect of univariate prognostic factors were performed using the Cox proportional hazards model. S-alkaline phosphatase (S-AP) and S-BGP were the only significant, independent prognostic factors.
...
PMID:The diagnostic and prognostic value of serum bone Gla protein (osteocalcin) in patients with recurrent breast cancer. 821 Sep 65

Tissue changes in rat incisors after direct pulp capping with calcium-beta-glycerophosphate (Ca-BGP) have been studied using light and electron microscopy. Immediately after pulp capping, Ca-BGP was converted to hydroxyapatite (HAP) at the cavity floor. At Day 1, the exposure site was covered with Ca-BGP-mediated mineralized tissue. Osteodentine had developed below this mineralized tissue at Day 3. Matrix vesicles (MV) were observed in the extracellular matrix between large cells and osteodentine. At Day 5, tubular dentine was observed below the osteodentine. Three days after the application of Ca(OH)2 in a control experiment, osteodentine had formed below the necrotic zone; however, tubular dentine was not observed at Day 5. These findings suggest that the applied Ca-BGP might be the source of Ca and inorganic phosphate (Pi) through hydrolysis by alkaline phosphatase (ALP), and that Ca-BGP-mediated mineralized tissue induces the early formation of tubular dentine.
...
PMID:Ultrastructure of wound healing following direct pulp capping with calcium-beta-glycerophosphate (Ca-BGP). 830 6

In this study we tested the effects of sodium fluoride (NaF) in serum-free cultures of human marrow stromal osteoblast-like [hMS(OB)] cells. NaF (10(-5) M) stimulated hMS(OB) cell proliferation up to 220% of control cultures. NaF alone did not increase type I collagen production, but in the presence of 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] (10(-9) M), NaF enhanced type I collagen production in a dose-dependent way to 300% of 1,25-(OH)2D3-treated control cultures. The production of alkaline phosphatase (ALP) and osteocalcin (bone gla protein, BGP) was also enhanced in the presence of 1,25-(OH)2D3 to 170 and 200%, respectively, of 1,25-(OH)2D3-treated controls. Our results suggest that 1,25-(OH)2D3 potentiates fluoride-mediated anabolism in hMS(OB) cell cultures and suggest that osteoblast precursors in bone marrow are targets for fluoride action.
...
PMID:1,25-dihydroxyvitamin D3 potentiates fluoride-stimulated collagen type I production in cultures of human bone marrow stromal osteoblast-like cells. 830 46

We have generated transgenic mice expressing the proto-oncogene c-fos from an H-2Kb class I MHC promoter as a tool to identify and isolate cell populations which are sensitive to altered levels of Fos protein. All homozygous H2-c-fosLTR mice develop osteosarcomas with a short latency period. This phenotype is specific for c-fos as transgenic mice expressing the fos- and jun-related genes, fosB and c-jun, from the same regulatory elements do not develop any pathology despite high expression in bone tissues. The c-fos transgene is not expressed during embryogenesis but is expressed after birth in bone tissues before the onset of tumor formation, specifically in putative preosteoblasts, bone-forming osteoblasts, osteocytes, as well as in osteoblastic cells present within the tumors. Primary and clonal cell lines established from c-fos-induced tumors expressed high levels of exogenous c-fos as well as the bone cell marker genes, type I collagen, alkaline phosphatase, and osteopontin/2ar. In contrast, osteocalcin/BGP expression was either low or absent. All cell lines were tumorigenic in vivo, some of which gave rise to osteosarcomas, expressing exogenous c-fos mRNA, and Fos protein in osteoblastic cells. Detailed analysis of one osteogenic cell line, P1, and several P1-derived clonal cell lines indicated that bone-forming osteoblastic cells were transformed by Fos. The regulation of osteocalcin/BGP and alkaline phosphatase gene expression by 1,25-dihydroxyvitamin D3 was abrogated in P1-derived clonal cells, whereas glucocorticoid responsiveness was unaltered. These results suggest that high levels of Fos perturb the normal growth control of osteoblastic cells and exert specific effects on the expression of the osteoblast phenotype.
...
PMID:Osteoblasts are target cells for transformation in c-fos transgenic mice. 833 93

In the last years, a parathyroid hormone (PTH)-related peptide (PTHrP) has been isolated from tumors associated with humoral hypercalcemia with malignancy (HHM). In the present work, we studied the effect of bovine PTH (bPTH)(1-34) and PTHrP(1-34) on tartrate-resistant acid phosphatase (TRAP), a marker of bone resorption, and alkaline phosphatase (AP) activities, and basal and vitamin D-stimulated osteocalcin (BGP) synthesis (markers of bone formation) in fetal rat calvaria cultures. After a 48-hour incubation period, both bPTH(1-34) and PTHrP(1-34) caused an increase in TRAP activity liberated in the medium with respect to control cultured calvaria. On the other hand, while after 2 or 4 h of incubation both bPTH(1-34) and PTHrP(1-34) caused a decrease in the AP activity liberated in the medium, after 48 h of incubation both peptides caused a significant increase in the AP liberated in the medium with respect to control cultures. With respect to BGP synthesis, both bPTH(1-34) and PTHrP(1-34) antagonized the 1,25-dihydroxyvitamin D3 stimulatory effect in calvaria cultures. We conclude that PTHrP(1-34) causes similar effects on bone, in organ cultures, to those caused by bPTH(1-34), namely an increase in both bone resorption and formation and a decrease in the vitamin D-stimulated BGP synthesis.
...
PMID:Effects of the (1-34) fragment of synthetic parathyroid hormone-related protein on tartrate-resistant acid phosphatase and alkaline phosphatase and alkaline phosphatase activities, and on osteocalcin synthesis, in cultured fetal rat calvaria. 837 26

A panel of bone turn-over markers was assessed in 75 normocalcemic patients bearing bone metastases from breast cancer (BC), and in 25 advanced/metastatic BC patients without clinical appearance of bone involvement. 115 healthy women, stratified in three subgroups according to age served as controls. Bone formation was investigated by measuring serum carboxyterminal propeptide of type I procollagen (PICP), Bone Gla Protein (BGP, osteocalcin), bone isoenzyme of alkaline phosphatase (BALP); bone resorption by measuring serum carboxyterminal telopeptide of type I collagen (ICTP), fasting urinary hydroxyproline/creatinine (OHPro/Cr) and calcium/creatinine (Ca/Cr). In patients with bone metastases the percent of supranormal values (higher than mean plus 2 SD of the age-matched controls) ranged between 25% and 40% for indices of bone formation, about 73% for both ICTP and OHPro/Cr and about 30% for Ca/Cr. The median levels of all bone turn-over markers were higher in bone metastatic patients than in those without apparent skeletal involvement, but significance was attained only for OHPro/Cr, Ca/Cr and BALP. Supranormal levels of ICTP and OHPro/Cr were also found in about 65-70% of patients without apparent skeletal involvement. ICTP and Ca/Cr significantly correlated with bone pain score, BALP, ICTP, Ca/Cr significantly correlated with the number of tumour appearances in bone. In conclusion, the bone resorption indices, ICTP and OHPro/Cr, are much more frequently elevated than bone formation indices in BC patients with or without skeletal involvement. Their potential use in the early detection of bone metastases is hampered by the insufficient knowledge on specificity. Among the biochemical markers evaluated, Ca/Cr, ICTP and BALP, due to correlation with clinical aspects, appear the most interesting for follow-up studies.
...
PMID:Biochemical picture of bone metabolism in breast cancer patients with bone metastases. 866 81

The aim of this work was to evaluate the response of different biochemical bone markers to tiludronate administration in Paget's disease of bone. Ten patients (five men and five women), 56-77 years old (67 +/- 6.5), were treated for 3 months with tiludronate tablets (400 mg/day). Bone formation markers: alkaline phosphatase (AP), bone alkaline phosphatase (bAP), osteocalcin (BGP), and procollagen I carboxyterminal propeptide (PICP) in serum; and bone resorption markers: serum cross-linked carboxyterminal telopeptides of type I collagen (ICTP), urinary hydroxyproline/creatinine (Hyp/Cr), pyridinoline/Cr (Pyr/Cr), and alpha-1 collagen chain products degradation (CrossLaps) were assessed. Samples were taken before and at monthly intervals for 3 months after treatment began. The results of the present work show that serum AP and bAP are sensitive and reliable biochemical markers of bone formation in the follow-up of tiludronate in this disease. Serum PICP shows less sensitivity than serum AP, and serum BGP is not indicated as biochemical marker in these types of studies. Urinary hydroxyproline seems to be the most reliable biochemical marker of bone resorption. More studies should be performed with urinary Pyr and CrossLaps determinations. Serum ICTP is not adequate for the follow-up of tiludronate treatment in Paget's disease of bone.
...
PMID:Variable efficacy of bone remodeling biochemical markers in the management of patients with Paget's disease of bone treated with tiludronate. 868 76

The purpose of this study was to investigate the effect of ovariectomy on osteoinductive activity in the bone in rat. Homograft implantation of decalcified humeral diaphysis from ovariectomized or sham-operated rats was performed and harvested after several time periods. A significant decrease in bone induction was found in terms of soft X-ray photography, alkaline phosphatase activity, mineral content and expression of osteocalcin (BGP; bone gla-protein) in the implants from the ovariectomized group in comparison to those from the sham-operated animals. This result suggested that the level of osteoinductive activity, probably due to bone morphogenetic protein, decreased in ovariectomized animals.
...
PMID:Ovariectomy decreases osteogenetic activity in rat bone. 870 22


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>

---